Current Report Filing (8-k)

Date : 02/02/2017 @ 9:15AM
Source : Edgar (US Regulatory)
Stock : Owc Pharmaceutical Research Corp. (QB) (OWCP)
Quote : 0.305  -0.011 (-3.48%) @ 4:05PM

Current Report Filing (8-k)

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): February 1, 2017

 

OWC PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)

 

Commission File No.: 0-54856

 

Delaware   98-0573566
(State of Incorporation)   (I.R.S. Employer Identification No.)
     
30 Shacham Street, P.O.B. 8324, Petach Tikva, Israel   4918103
(Address of Principal Executive Offices)   (ZIP Code)

 

Registrant’s Telephone Number, including area code: 972 (0) 3-758-2657

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

     
   

 

Item 8.01 Other Events.

 

OWC Pharmaceutical Research Corp., OTCQB: OWCP (the “Registrant”), through its wholly-owned Israeli subsidiary, One World Cannabis Ltd. (“OWC Ltd”), has been conducting study on the efficacy its proprietary cannabinoid-based topical cream for the treatment of skin conditions generally and psoriasis specifically, which commenced in November, 2016 (the “Study”).

 

On February 1, 2017, following the very encouraging results that have been achieved at the mid-point of the Study, the Registrant’s Board of Directors and the management and scientific personnel of OWC Ltd have determined to extend the size and scope of the Study for the purpose of, among other things, checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins). Despite extending its size and scope of the Study, the Registrant expects to compete the Study within the same projected time frame.

 

     
   

 

  OWC Pharmaceutical Research Corp.
     
  By: /s/ Mordechai Bignitz
  Name: Mordechai Bignitz
  Title: Chief Executive Officer

 

Date: February 2, 2017

 

     
   

 

 

OWC Pharmaceutical Research (USOTC:OWCP)
Historical Stock Chart

1 Year : From Aug 2016 to Aug 2017

Click Here for more OWC Pharmaceutical Research Charts.

OWC Pharmaceutical Research (USOTC:OWCP)
Intraday Stock Chart

Today : Wednesday 23 August 2017

Click Here for more OWC Pharmaceutical Research Charts.

Latest OWCP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.